Search Results

Qpex Biopharma, Inc. today announced the exercise of a $10 million option from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, to support the advancement of the company’s antibiotic clinical development program.

Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has entered into a definitive agreement pursuant to which Shionogi Inc. will acquire Qpex Biopharma, Inc.

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, announced that it entered into definitive agreements with Qpex Biopharma and third parties in connection with the acquisition of Qpex by Shionogi.

Pathogens for antimicrobial resistance may still be a bit off peoples’ radar, but the lessons from unpreparedness of COVID-19 are in the mind of Qpex.

The acquisition of the privately-held company will bring its novel, investigational beta-lactamase inhibitors and other antimicrobials into the Japanese pharma’s pipeline.

Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23.

Qpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens.

Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., announced the upcoming presentation of new data at IDWeek 2023 on its investigational oral antiviral for COVID-19, ensitrelvir, and Fetroja®, an antibiotic marketed under the brand name Fetcroja® in Europe.

Qpex Biopharma, Inc. today announced the company will present new clinical data for their β-lactamase inhibitor xeruborbactam (formerly QPX7728) and synthetic lipopeptide QPX9003 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held on April 23-26, 2022.

Qpex Biopharma, Inc. announced initiation of a Phase 1 study of QPX9003, a next generation intravenous (IV)-administered synthetic polymyxin for infections.